Entity

Time filter

Source Type

York, United Kingdom

Owen K.,University of Leeds | Wilshaw S.-P.,University of Leeds | Homer-Vanniasinkam S.,Vascular Institute | Bojar R.A.,Evocutis | And 2 more authors.
European Journal of Vascular and Endovascular Surgery | Year: 2012

Several studies have reported biological vascular grafts to be more resistant to microbial infection than synthetic counterparts in vivo. Indeed, small intestinal submucosa (SIS) materials have previously been reported to be antimicrobial. The aim of this study was to assess the antimicrobial activity and the ability to resist biofilm formation of a novel acellular vascular graft and compare it to commercially available alternatives using a range of organisms: MRSA, MSSA, Staphylococcus epidermidis, Enterococcus faecalis, Escherichia coli, Klebsiella pneumonia, Pseudomonas aeruginosa and Candida albicans. This was achieved using a modified disk diffusion assay and extraction of the materials into solution followed by minimum inhibitory concentration assays. To assess resistance to biofilm formation a novel biofilm assay was developed which compared the total colony forming units (CFU) recovered from each material and identification of the percentage of CFU which were loosely attached, residing within the biofilm or attached to the biomaterial. The results indicated a lack of antimicrobial activity for all materials tested, including SIS. The biological materials were more resistant to the formation of a biofilm compared to Dacron. © 2012 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved. Source


Trademark
Tissue Regenix | Date: 2014-06-06

Replacement materials for animal and human tissue, namely, biological tissues, namely, skin, skin grafts, ureter tissue, bladders, tendons, cartilage, ligaments, blood vessels, nerves, soft tissue for use in the heart and pericardium intended for subsequent implantation; Replacement materials for animal and human tissue, namely, implants comprising living tissue or comprising biological tissue cultures or comprising processed tissues derived from humans and animals intended for subsequent implantation comprising bone, skin, skin grafts, ureters, bladders, tendons, cartilage, ligaments, blood vessels, nerves, soft tissue for use in the heart and pericardium; surgical implants comprising living tissue; surgical implants comprising living tissue, namely, vascular patches, meniscus, aortic heart valves, blood vessels, ligaments, cartilage, bone; tissue regeneration materials, namely, human allograft or autograft tissue; Biological implants, namely, a vital processed human or animal connective tissue, namely, xenograft tissue; biological implants for guided tissue regeneration, namely, a vital processed human or animal connective tissue; arterial vascular grafts; human allograft tissue formed for use as a surgical patch; Biological implants, namely, a vital processed human or animal connective tissue, namely, heart valve implants comprising human or animal tissues; small diameter skin grafts. Surgical implants comprising textile material to encourage the growth of tissue, namely, medical, surgical and orthopaedics implants made of artificial textile materials; surgical implants and mesh made of synthetic materials for use in soft tissue; surgical and intravascular implants comprised of artificial textile material. Treatment of living cells and tissue, namely, removing immunogenic materials. Medical research and scientific research in the field of replacement tissues for humans and animals, regenerative medical devices.


Patent
Tissue Regenix | Date: 2014-07-29

The invention provides an improved method of producing a natural, acellular matrix scaffold for subsequent use in tissue-engineered replacement of tissues such as the bladder. Decellularisation is carried out on an expanded or distended bladder and the product retains the strength and compliance of natural material. The invention also provides use of the matrix scaffolds as wound healing material and to investigate tissue structure and function in vitro.


Grant
Agency: Cordis | Branch: FP7 | Program: BSG-SME | Phase: SME-1 | Award Amount: 1.47M | Year: 2011

Regenerative Medicine (use of cells and tissue to replace or heal impaired functions in the body, RM) is one of the fastest growing areas in todays medicine, and has the potential to offer treatment to patients with diseases that are currently untreatable. In many new areas of RM there is however a need to improve the outcome of RM concepts and technologies for it to become a viable option to traditional medicine, or even to motivate the risk of clinical trials and treatments. One of the main problems in several RM areas is that a large portion of the cell and tissue material is lost or made dysfunctional during and shortly after transplantation and that the transplant does not connect to the host tissue as a functional new graft. The specific scientific objective of this project is twofold: 1) to clinically test and prove that Corline Heparin Surfaces (CHS) can be used to protect donated human insulin producing cells that are transplanted to severe cases of Diabetes Type 1 patients, and 2) to broaden the application of the technology and show that the CHS technology can function as a protective and revascularization promoting technology for other Regenerative Medicine areas. The goal is to show CHSs further applicability to Liver Cell therapy, Xeno transplantation of Islet of Langerhans and to Tissue Engineering In addition to the detailed scientific objective, this project has a specific technological objective. The technological objective of this project is to, in partnerships with the participating SMEs, improve European top grade clinical Regenerative Medicine products by combining them with the CHS technology, transferring the application knowledge and integrating the CHS technology into the partners cell and tissue production processes, and to set up a reliable sourcing chain with supply and production of reagents and tissue products to end-user.


Patent
Tissue Regenix | Date: 2014-07-29

The invention provides an improved method of producing a natural, acellular matrix scaffold for subsequent use in tissue-engineered replacement of tissues such as the bladder. Decellularisation is carried out on an expanded or distended bladder and the product retains the strength and compliance of natural material. The invention also provides use of the matrix scaffolds as wound healing material and to investigate tissue structure and function in vitro.

Discover hidden collaborations